WO2005115397A3 - Compositions and treatments for modulating kinase and/or hmg-coa reductase - Google Patents

Compositions and treatments for modulating kinase and/or hmg-coa reductase Download PDF

Info

Publication number
WO2005115397A3
WO2005115397A3 PCT/US2005/014833 US2005014833W WO2005115397A3 WO 2005115397 A3 WO2005115397 A3 WO 2005115397A3 US 2005014833 W US2005014833 W US 2005014833W WO 2005115397 A3 WO2005115397 A3 WO 2005115397A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
coa reductase
compositions
treatments
kinase
Prior art date
Application number
PCT/US2005/014833
Other languages
French (fr)
Other versions
WO2005115397A2 (en
Inventor
John Griffin
Original Assignee
Pharmix Corp
John Griffin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmix Corp, John Griffin filed Critical Pharmix Corp
Publication of WO2005115397A2 publication Critical patent/WO2005115397A2/en
Publication of WO2005115397A3 publication Critical patent/WO2005115397A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides compositions of matter, kits and methods for their use in the treatment of kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating immuno-compromised and/or cardiovascular conditions in an animal subject by modulating one or more MAP kinase(s) and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of modulators of MAP kinases, HMG-CoA reductase, or both for use in the practice of the present invention.
PCT/US2005/014833 2004-04-29 2005-04-29 Compositions and treatments for modulating kinase and/or hmg-coa reductase WO2005115397A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56711804P 2004-04-29 2004-04-29
US60/567,118 2004-04-29
US63068304P 2004-11-23 2004-11-23
US63068404P 2004-11-23 2004-11-23
US60/630,683 2004-11-23
US60/630,684 2004-11-23

Publications (2)

Publication Number Publication Date
WO2005115397A2 WO2005115397A2 (en) 2005-12-08
WO2005115397A3 true WO2005115397A3 (en) 2006-07-13

Family

ID=35451387

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/014833 WO2005115397A2 (en) 2004-04-29 2005-04-29 Compositions and treatments for modulating kinase and/or hmg-coa reductase
PCT/US2005/014843 WO2006028524A2 (en) 2004-04-29 2005-04-29 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014843 WO2006028524A2 (en) 2004-04-29 2005-04-29 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase

Country Status (3)

Country Link
EP (1) EP1755607A2 (en)
JP (1) JP2007535558A (en)
WO (2) WO2005115397A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329703B2 (en) 2005-02-15 2012-12-11 Xtl Biopharmaceuticals Ltd. Pyrazole compounds
US20090227602A1 (en) * 2005-10-28 2009-09-10 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US7923004B2 (en) 2006-10-13 2011-04-12 Xtl Biopharmaceuticals Ltd. 4-ethynyl pyrazole derivative compounds and methods for treatment of HCV
AU2009299555B2 (en) 2008-10-02 2014-01-16 Respivert Limited p38 map kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
NZ593104A (en) 2008-12-11 2012-11-30 Respivert Ltd P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2308866A1 (en) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
HUE039687T2 (en) 2013-10-17 2019-01-28 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
TW202104231A (en) 2019-04-12 2021-02-01 美商藍印藥品公司 Compositions and methods for treating kit- and pdgfra-mediated diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177121B1 (en) * 1997-09-29 2001-01-23 Purdue Research Foundation Composition and method for producing low cholesterol eggs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI894648A (en) * 1988-10-03 1990-04-04 Glaxo Group Ltd CHEMICAL FOERENINGAR.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177121B1 (en) * 1997-09-29 2001-01-23 Purdue Research Foundation Composition and method for producing low cholesterol eggs

Also Published As

Publication number Publication date
WO2006028524A2 (en) 2006-03-16
WO2005115397A2 (en) 2005-12-08
EP1755607A2 (en) 2007-02-28
JP2007535558A (en) 2007-12-06
WO2006028524A3 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
WO2005115397A3 (en) Compositions and treatments for modulating kinase and/or hmg-coa reductase
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2005107747A3 (en) Diindolymethane formulations for the treatment of leiomyomas
WO2007011962A3 (en) Treatment of cancer
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
WO2008046003A3 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2007079164A3 (en) Protein kinase inhibitors
WO2010006086A3 (en) Kinase inhibitors and methods of use
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2005116025A3 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
WO2007149287A3 (en) Transfer factor compositions and methods
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2005048948A3 (en) Urea derivatives as kinase modulators
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
EP2532657A3 (en) Compounds and methods of use
DE602006014848D1 (en) PYRAZOLOPYRIMIDINES AS INHIBITORS OF CYCLINE DEPTHS
WO2008030883A3 (en) Treatment of cancer
WO2007002744A3 (en) Aluminum phosphate based microspheres
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2005077954A3 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase